Sign In to Follow Application
View All Documents & Correspondence

Process&Nbsp;For The Preparation Of Purified Sacrosidase

Abstract: The present invention relates to a process for the purification of Sacrosidase, which comprises elution of crude Sacrosidase solution on an anion exchange chromatography, a hydrophobic interaction chromatography, and then an ultrafiltration to obtain purified Sacrosidase.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
13 May 2019
Publication Number
47/2020
Publication Type
INA
Invention Field
CHEMICAL
Status
Email
Parent Application

Applicants

AUROZYMES LIMITED
AUROBINDO PHARMA LIMITED THE WATER MARK BUILDING, PLOT NO. 11, SURVEY NO. 9, KONDAPUR, HITECH CITY, HYDERABAD - 500 084.TELANGANA, INDIA.

Inventors

1. JONATHAN WILLIAM WIFFEN
AUROBINDO PHARMA LIMITED THE WATER MARK BUILDING, PLOT NO. 11, SURVEY NO. 9, KONDAPUR, HITECH CITY, HYDERABAD - 500 084.TELANGANA, INDIA.
2. EMMANUEL VIJAY PAUL
AUROBINDO PHARMA LTD THE WATER MARK BUILDING, PLOT NO.11, SURVEY NO.9, KONDAPUR, HITECH CITY, HYDERABAD,500084.TELANGANA, INDIA.

Specification

1. A process for the purification of Sacrosidase, comprising the steps of:
i) a microfiltration;
ii) an ultrafiltration;
iii) an anion exchange chromatography;
iv) a hydrophobic interaction chromatography, and
v) an ultrafiltration to obtain purified Sacrosidase.
2. The process as claimed in claim 1, wherein the microfiltration of step (i) comprises a material of membranes having a cut-off of 0.05 to l.Oum.
3. The process as claimed in claim 1, wherein the microfiltration process of step (i) is performed with a cross flow microfiltration to obtain permeate.
4. The process as claimed in claim 1, wherein the ultrafiltration of step (ii) is carried out on semi-permeable membrane having a membrane area less than 0.5m2 to concentrate the permeate.
5. The process as claimed in claim 1, wherein the anion exchange chromatography of step (iii) involves the use of a resin, comprises polymeric resin, unosphere Q, sepharose and polymethacrylate.
6. The process as claimed in claim 1, wherein the anion exchange chromatography is eluted with a buffer to obtain crude Sacrosidase.
7. The process as claimed in claim 1, wherein the hydrophobic interaction chromatography (HIC) of step (iv) involves use of resin, comprises HP-20, Phenyl Sepharose, Butyl Sepharose, Octyl Sepharose, Capto Phenyl,

Toyopearl Butyl, Toyopearl Phenyl, Toyopearl Hexyl, Toyopearl Ether, and Toyopearl PPG to pack the column.
8. The process as claimed in claim 1, wherein the interaction chromatography (HIC) is eluted with an equilibration buffer (K2HPO4, KH2PO4, (NH^SCU and water) to obtain pure fraction of Sacrosidase solution.
9. The process as claimed in claim 1, wherein the ultrafiltration of step (v) is performed with the membrane area of less than 0.4m2 to concentrate the obtained purified Sacrosidase.
10. A process for the purification of Sacrosidase having SEQ ID No. 1, which has activity of activity units 10,000 -12000 IU/ml, comprising the steps of:

a) eluting the Sacrosidase solution on a resin packed anion exchange chromatography;
b) eluting the obtained crude Sacrosidase solution on a HP20 resin packed hydrophobic interaction chromatography, and
c) concentrating the pure fractions of step b) on an ultrafiltration to obtain purified Sacrosidase.

Documents

Application Documents

# Name Date
1 Form2 Title Page_Provisional_13-05-2019.pdf 2019-05-13
2 Form1_As Filed_13-05-2019.pdf 2019-05-13
3 Description Provisional_As Filed_13-05-2019.pdf 2019-05-13
4 Correspondence by Applicant_ Form 1, Form 2_13-05-2019.pdf 2019-05-13
5 201941018974-Form2 (Title Page)_Complete_11-05-2020.pdf 2020-05-11
6 201941018974-Form 5_After Provisional_11-05-2020.pdf 2020-05-11
7 201941018974-Description Complete_After Provisional_11-05-2020.pdf 2020-05-11
8 201941018974-Correspondence_After Provisional_11-05-2020.pdf 2020-05-11
9 201941018974-Claims_After Provisional_11-05-2020.pdf 2020-05-11
10 201941018974-Abstract_After Provisional_11-05-2020.pdf 2020-05-11
11 201941018974-Form3_After Filing_15-04-2021.pdf 2021-04-15
12 201941018974-Correspondence_Form3_15-04-2021.pdf 2021-04-15